Faut-il encore utiliser l'étomidate ?

Translated title of the contribution: Should etomidate still be used?

J. F. Payen, M. Vinclair, C. Broux, P. Faure, O. Chabre

Research output: Contribution to journalArticle

Abstract

Etomidate blocks the cortisol synthesis by specifically inhibiting the activity of 11β-hydroxylase, resulting in a primary adrenal insufficiency. Therefore, a serum accumulation of 11β-deoxycortisol and a low secretion of serum cortisol must be required as diagnostic criteria to assign that adrenal impairment to the drug. These requirements have been rarely fulfilled in studies exploring the contribution of etomidate to the adrenal insufficiency despite numerous causes of adrenal derangement. In critically ill patients without sepsis, a single dose of etomidate results in a wide adrenal inhibition, reversible in 48 h after etomidate administration. Although there are still uncertainties as to whether etomidate directly affects mortality and morbidity, it seems preferable to avoid the use of etomidate in patients with severe sepsis and septic shock. In patients with severe traumatic brain injury, arterial hypotension is one of major factors of poor outcome and can be prevented with the use of etomidate for facilitating tracheal intubation. Substitutive opotherapy with low doses of hydrocortisone should be assessed after a single dose of etomidate for critically ill patients.

Original languageFrench
Pages (from-to)915-919
Number of pages5
JournalAnnales Francaises d'Anesthesie et de Reanimation
Volume27
Issue number11
DOIs
StatePublished - Nov 2008
Externally publishedYes

Fingerprint

Etomidate
Hydrocortisone
Critical Illness
Sepsis
Cortodoxone
Addison Disease
Adrenal Insufficiency
Septic Shock
Mixed Function Oxygenases
Serum
Intubation
Hypotension
Uncertainty
Morbidity
Mortality

Keywords

  • Adrenal inhibition
  • Cortisol
  • Etomidate
  • ICU

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Payen, J. F., Vinclair, M., Broux, C., Faure, P., & Chabre, O. (2008). Faut-il encore utiliser l'étomidate ? Annales Francaises d'Anesthesie et de Reanimation, 27(11), 915-919. https://doi.org/10.1016/j.annfar.2008.09.016

Faut-il encore utiliser l'étomidate ? / Payen, J. F.; Vinclair, M.; Broux, C.; Faure, P.; Chabre, O.

In: Annales Francaises d'Anesthesie et de Reanimation, Vol. 27, No. 11, 11.2008, p. 915-919.

Research output: Contribution to journalArticle

Payen, JF, Vinclair, M, Broux, C, Faure, P & Chabre, O 2008, 'Faut-il encore utiliser l'étomidate ?', Annales Francaises d'Anesthesie et de Reanimation, vol. 27, no. 11, pp. 915-919. https://doi.org/10.1016/j.annfar.2008.09.016
Payen, J. F. ; Vinclair, M. ; Broux, C. ; Faure, P. ; Chabre, O. / Faut-il encore utiliser l'étomidate ?. In: Annales Francaises d'Anesthesie et de Reanimation. 2008 ; Vol. 27, No. 11. pp. 915-919.
@article{f32dc05c874f4ecbafbc9a271dcd9683,
title = "Faut-il encore utiliser l'{\'e}tomidate ?",
abstract = "Etomidate blocks the cortisol synthesis by specifically inhibiting the activity of 11β-hydroxylase, resulting in a primary adrenal insufficiency. Therefore, a serum accumulation of 11β-deoxycortisol and a low secretion of serum cortisol must be required as diagnostic criteria to assign that adrenal impairment to the drug. These requirements have been rarely fulfilled in studies exploring the contribution of etomidate to the adrenal insufficiency despite numerous causes of adrenal derangement. In critically ill patients without sepsis, a single dose of etomidate results in a wide adrenal inhibition, reversible in 48 h after etomidate administration. Although there are still uncertainties as to whether etomidate directly affects mortality and morbidity, it seems preferable to avoid the use of etomidate in patients with severe sepsis and septic shock. In patients with severe traumatic brain injury, arterial hypotension is one of major factors of poor outcome and can be prevented with the use of etomidate for facilitating tracheal intubation. Substitutive opotherapy with low doses of hydrocortisone should be assessed after a single dose of etomidate for critically ill patients.",
keywords = "Adrenal inhibition, Cortisol, Etomidate, ICU",
author = "Payen, {J. F.} and M. Vinclair and C. Broux and P. Faure and O. Chabre",
year = "2008",
month = "11",
doi = "10.1016/j.annfar.2008.09.016",
language = "French",
volume = "27",
pages = "915--919",
journal = "Anaesthesia, critical care & pain medicine",
issn = "0750-7658",
publisher = "Elsevier BV",
number = "11",

}

TY - JOUR

T1 - Faut-il encore utiliser l'étomidate ?

AU - Payen, J. F.

AU - Vinclair, M.

AU - Broux, C.

AU - Faure, P.

AU - Chabre, O.

PY - 2008/11

Y1 - 2008/11

N2 - Etomidate blocks the cortisol synthesis by specifically inhibiting the activity of 11β-hydroxylase, resulting in a primary adrenal insufficiency. Therefore, a serum accumulation of 11β-deoxycortisol and a low secretion of serum cortisol must be required as diagnostic criteria to assign that adrenal impairment to the drug. These requirements have been rarely fulfilled in studies exploring the contribution of etomidate to the adrenal insufficiency despite numerous causes of adrenal derangement. In critically ill patients without sepsis, a single dose of etomidate results in a wide adrenal inhibition, reversible in 48 h after etomidate administration. Although there are still uncertainties as to whether etomidate directly affects mortality and morbidity, it seems preferable to avoid the use of etomidate in patients with severe sepsis and septic shock. In patients with severe traumatic brain injury, arterial hypotension is one of major factors of poor outcome and can be prevented with the use of etomidate for facilitating tracheal intubation. Substitutive opotherapy with low doses of hydrocortisone should be assessed after a single dose of etomidate for critically ill patients.

AB - Etomidate blocks the cortisol synthesis by specifically inhibiting the activity of 11β-hydroxylase, resulting in a primary adrenal insufficiency. Therefore, a serum accumulation of 11β-deoxycortisol and a low secretion of serum cortisol must be required as diagnostic criteria to assign that adrenal impairment to the drug. These requirements have been rarely fulfilled in studies exploring the contribution of etomidate to the adrenal insufficiency despite numerous causes of adrenal derangement. In critically ill patients without sepsis, a single dose of etomidate results in a wide adrenal inhibition, reversible in 48 h after etomidate administration. Although there are still uncertainties as to whether etomidate directly affects mortality and morbidity, it seems preferable to avoid the use of etomidate in patients with severe sepsis and septic shock. In patients with severe traumatic brain injury, arterial hypotension is one of major factors of poor outcome and can be prevented with the use of etomidate for facilitating tracheal intubation. Substitutive opotherapy with low doses of hydrocortisone should be assessed after a single dose of etomidate for critically ill patients.

KW - Adrenal inhibition

KW - Cortisol

KW - Etomidate

KW - ICU

UR - http://www.scopus.com/inward/record.url?scp=56949098260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56949098260&partnerID=8YFLogxK

U2 - 10.1016/j.annfar.2008.09.016

DO - 10.1016/j.annfar.2008.09.016

M3 - Article

C2 - 18980826

AN - SCOPUS:56949098260

VL - 27

SP - 915

EP - 919

JO - Anaesthesia, critical care & pain medicine

JF - Anaesthesia, critical care & pain medicine

SN - 0750-7658

IS - 11

ER -